There's More to Gilead Sciences' Remdesivir Data Than Meets the Eye
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy for combating the outbreak.
Last week, clinical data from Gilead Sciences (NASDAQ: GILD) shared with STAT News point to a potential respite in the COVID-19 crisis and possibly significant upside for Gilead investors.
Image Source: Getty Images
Source Fool.com
